A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. [electronic resource]
Producer: 20130503Description: 5489-98 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Carboplatin -- administration & dosage
- Dasatinib
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm Staging
- Ovarian Neoplasms -- drug therapy
- Paclitaxel -- administration & dosage
- Protein Kinase Inhibitors -- administration & dosage
- Pyrimidines -- administration & dosage
- Thiazoles -- administration & dosage
- src-Family Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.